Science

Jan 30, 2025, 13:35

Myeloma Paper of the Day, January 30th, suggested by Robert Orlowski

Robert Orlowski, Florence Maude Thomas Cancer Research Professor at The University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) may safely induce disease remissions in relapsed, refractory myeloma without CRS or ICANS though median PFS was only 6.0 months.”

“Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma”

Authors: Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo, Lawrence Lum, Deborah Glass, Jee Park, Michele Donato, David Siegel, Tania Felizardo and Daniel Fowler.

More posts featuring Robert Orlowski.

Aniko Szabo Binod Dhakal cancer Daniel Fowler David Siegel Deborah Glass Jee Park Lawrence Lum Michele Donato multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Parameswaran Hari RAPA-201 Robert Orlowski Saurabh Chhabra Tania Felizardo

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience

Highlights from TTLC2025

KIMMTRAK (Tebentafusp) uses in Cancer: Dosages, Indications, Expectations and more